Rockefeller Capital Management
AXDX

Rockefeller Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

Rockefeller Capital Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50
Closed – – 2126
2022
Q4 		$0 Hold
50
– – ﹤0.01% 3848
2022
Q3 		$0 Hold
50
– – ﹤0.01% 3878
2022
Q2 		$0 Hold
50
– – ﹤0.01% 4093
2022
Q1 		$0 Buy
+50
New +$1.42K ﹤0.01% 3860

Other funds holding AXDX

GAM
Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return

Rockefeller Capital Management's AXDX Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Accelerate Diagnostics (AXDX) in Q1 2023, closing a stake of 50 shares.

Rockefeller Capital Management first reported a position in AXDX in Q1 2022 and held it in 4 quarters. The position peaked at $0 in Q4 2022. 66 funds tracked by Wall St. Rank hold AXDX as of Q1 2023.

  • Rockefeller Capital Management reported no remaining Accelerate Diagnostics position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 50 Accelerate Diagnostics shares in Q1 2023.
  • Rockefeller Capital Management first reported a position in Accelerate Diagnostics in Q1 2022 and held it in 4 quarters.
  • Rockefeller Capital Management's Accelerate Diagnostics position peaked at $0 in Q4 2022.
  • 66 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.